Topical Silver Nanoparticles for Microbial Activity
Study Details
Study Description
Brief Summary
Silver nanoparticles are one of most nanoparticles use nowadays in the research area because it has specific physical and chemical properties, in medical fields silver nanoparticles can involve in diagnostic and treatment processes. Silver nanoparticles have antibacterial, antiviral, antifungal, antiangiogenic, antioxidant, cosmetics, antitumor, anti-inflammatory, the drug carrier, imaging, water treatment, and biosensing effects. Silver nanoparticles prepared with reducing agent tri-sodium citrate then incorporated in a topical cream to obtain a significant inhibition of the bacterial strains, inhibition of growth of bacterial strains in the face or other parts in the bodies.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
-
Preparation of vanishing cream Vanishing cream is an emulsion base which is oil in water, the oil phase gives the cream shine and pearl look because of stearic acid in the oil. To form an emulsion, the alkali will react with stearic acid to form stearate soap. Then mix sodium hydroxide (NaOH) with potassium hydroxide (KOH) to give cream hard and soft properties.
-
Preparation of cream containing silver nanoparticles Silver nanoparticles will be produced by using the reduction reaction method. The reaction involves heating silver nitrate at a high temperature with adding a reducing agent, the particles will produce as silver nanoparticles in liquid form.
-
Characterization of the Vanishing cream containing drug:
3.1. Drug content: The amount of drug in cream will be determined by taking 100 mg of the cream formulation and dissolve it in 10 mL of methanol after that it will be filtrated. In addition, it will be analyzed the content of drug spectrophotometrically using (UV-VIS) at specific λmax.
3.2. Irritation to skin: In this test, the cream formulation will be applied to four healthy volunteers which they should not have any sensitivity to the drug. They will inform about the nature of the formulation and obtain a written approval from them about the irritation effect of the formulated cream.
- Anti-microbial studies:
The antifungal action for formula will be studied using different 6 groups volunteers The inhibition microbial activity for all formulae were compared with known standard antimicrobial drugs.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Silver nanoparticles group A group of volunteers infected with Tinea pedis, Capitis and Versicolor received Topical silver nanoparticles in different dosage forms. |
Drug: Silver nanoparticles
The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
Other Names:
|
| Placebo Comparator: Topical approved anti-microbial gel A group of volunteers infected with Tinea pedis, Capitis and Versicolor received placebo cream. |
Drug: Topical approved anti-microbial gel
The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The antimicrobial activity of silver nanoparticles in the two groups of control and an infected patient will be determined. Each group will be of 6 volunteers, each one will be controlled for the CTCAE. [Six months]
The formulated silver nanoparticles are expected to be with anti-microbial after applying activity with infected patients even systemically or topically. The nanoparticles will be examined on two groups of patients (control group, and patient with fungal or microbial infections). Moreover, the obtained silver nanoparticles are expected to highly internalized and disease targeted. The results will be compared with control groups to prove the anti-microbial Activity. The progress of treating the patient will be noticed by completely disappear of fungal infection.
Secondary Outcome Measures
- Stable topical anti-microbial silver nanoparticles [three months]
Stability test will be studied for dosage forms. The test will carried out by standing the products on shelf life for three months. The stability test will be recorded using high performance liquid chromatography each thee days.
Eligibility Criteria
Criteria
Inclusion Criteria:
- It is important to follow up and collect data, preferably for six months for the local and systemic activity of silver nanoparticles, to establish whether the infection recurrent or not.
Exclusion Criteria:
- Larger numbers of participants having a different kind of skin infection are needed to test efficiency drug in order to produce more reliable data.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Buraidah Clinic | Buraidah | Al Qassim | Saudi Arabia | 51171 |
Sponsors and Collaborators
- Ahmed A. H. Abdellatif
Investigators
- Principal Investigator: Ahmed AH Abdellatif, PhD, Qassim University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AlAzharSilver